FDA Certification
Li, W., Cai, R., Yin, B., Zhou, Y., Dong, X., Li, W., & Wen, J
Some formulations also carry indications for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
These side effects are usually temporary and diminish as your body becomes accustomed to the injections
The experimental shot helped people lose almost 11% of their body weight -- less than the currently available injections Wegovy and Zepbound